Dougherty & Co Affirms 'Buy' on Uroplasty (UPI); Allergan's (AGN) Entry Is Slight Positive...Near-Term
Tweet Send to a FriendGet Alerts UPI Hot Sheet
Price: $2.18 +5.31%
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade UPI Now!
Dougherty & Co affirms 'Buy' on Uroplasty (NASDAQ: UPI) price target lowered from $6.50 to $5.
Analyst, Deepak Chaulagai, said, "We think the potential entry of Allergan (NYSE: AGN) into the idiopathic market could bring further awareness to the OAB market – a slight positive for UPI. On the other hand, competition could slow UPI’s growth over the long-term. However, we think UPI has ample room to grow with a superior therapy to serve a large and underserved $3b+ OAB market. That is why we are affirming our Rating but lowering our price target (PT) to $5."
For an analyst ratings summary and ratings history on Uroplasty click here. For more ratings news on Uroplasty click here.
Shares of Uroplasty closed at $3.14 yesterday, with a 52 week range of $2.66-$9.11.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Deepak Chaulagai, said, "We think the potential entry of Allergan (NYSE: AGN) into the idiopathic market could bring further awareness to the OAB market – a slight positive for UPI. On the other hand, competition could slow UPI’s growth over the long-term. However, we think UPI has ample room to grow with a superior therapy to serve a large and underserved $3b+ OAB market. That is why we are affirming our Rating but lowering our price target (PT) to $5."
For an analyst ratings summary and ratings history on Uroplasty click here. For more ratings news on Uroplasty click here.
Shares of Uroplasty closed at $3.14 yesterday, with a 52 week range of $2.66-$9.11.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- UBS Raises PT on Tesoro (TSO)
- Goldman Sachs Upgrades Meritor (MTOR) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
